Premier Fund Managers Ltd Invests $693,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Premier Fund Managers Ltd acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 6,458 shares of the medical equipment provider's stock, valued at approximately $693,000.

Other institutional investors have also modified their holdings of the company. Signaturefd LLC lifted its position in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in shares of Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock valued at $1,834,000 after purchasing an additional 100 shares during the period. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares during the period. GAMMA Investing LLC increased its position in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after buying an additional 146 shares during the period. Finally, Moody National Bank Trust Division lifted its stake in Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock valued at $1,203,000 after buying an additional 162 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Up 7.1 %

Shares of NASDAQ LNTH traded up $5.60 during midday trading on Wednesday, hitting $85.03. The company had a trading volume of 960,534 shares, compared to its average volume of 1,009,477. The business has a 50-day simple moving average of $104.07 and a two-hundred day simple moving average of $96.66. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The firm has a market capitalization of $5.91 billion, a price-to-earnings ratio of 14.07 and a beta of 0.51.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of recent research reports. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Friday, November 8th. B. Riley increased their price objective on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. Truist Financial reaffirmed a "buy" rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities dropped their price objective on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.